Belpointe Asset Management’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
Belpointe Asset Management's TGTX Position: Q3 2026 in Review
Belpointe Asset Management reduced its TG Therapeutics (TGTX) stake by 44% in Q3 2026, selling an estimated $1.21M and leaving 28,317 shares worth $1.58M. The position accounts for 0.04% of the portfolio, ranked #385.
Belpointe Asset Management first reported a position in TGTX in Q3 2018 and has held it in 5 quarters since. The position peaked at $2.79M in Q2 2026. 455 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- Belpointe Asset Management held 28,317 shares of TG Therapeutics worth $1.58M as of Q3 2026.
- Belpointe Asset Management sold 22,402 TG Therapeutics shares in Q3 2026, an estimated $1.21M.
- TG Therapeutics made up 0.04% of Belpointe Asset Management's portfolio in Q3 2026, its #385 holding.
- Belpointe Asset Management first reported a position in TG Therapeutics in Q3 2018 and has held it in 5 quarters since.
- Belpointe Asset Management's TG Therapeutics position peaked at $2.79M in Q2 2026.
- 455 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.